Compare General Dynamics Corporation (GD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Pfizer Inc — how do they compare? General Dynamics Corporation trades at $327.6 (market cap $89.26B), while Pfizer Inc trades at $27.69 (market cap $158.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Pfizer Inc for 158 Days on average.
| GD | PFE | |
|---|---|---|
Market Cap | $89.26B | $158.56B |
Volume | 1,496,273 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $395.97 | $29.02 |
52-Week Low | $312.53 | $23.67 |
Typical Hold Time | 85 Days | 158 Days |
Enterprise Value | $94.40B | $210.06B |
Dividend Yield | 1.93% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $326.63, down 1.42% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, supported by robust Pentagon spending and dividend reliability. Technical indicators show oversold conditions with RSI at 11.03, though moving averages signal bearish momentum.
GD presents a compelling value opportunity with attractive valuation metrics (P/E 19.92) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend stability provide downside protection. The stock offers 28% upside to consensus targets with defensive characteristics suitable for long-term investors.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
